1. BDTX will host a webcast on December 3 to discuss clinical trial results. 2. The trial focuses on silevertinib for treating NSCLC and glioblastoma. 3. The webcast may influence investor sentiment based on trial outcomes. 4. BDTX's MasterKey therapies target oncogenic mutations in cancer treatments. 5. Investors can access the webcast via the company’s investor website.
FAQ
Why Bullish?
Positive results from clinical trials often lead to stock price increases, as seen previously with biotech firms like Novavax after vaccine updates. The technology targeting oncogenic mutations is innovative and could enhance BDTX's value.
How important is it?
The webcast's results will significantly affect BDTX's market perception. Investors are likely to respond quickly based on clinical data revealed, aligning with timing patterns observed in similar biotech updates.
Why Short Term?
The webcast's timing is crucial; immediate reactions may come post-announcement. Historical cases show swift stock movements post-clinical update announcements, such as with Moderna.
Webcast to be held Wednesday, December 3, at 8:00am ET
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET.
Webcast information
The webcast can be accessed under "Events and Presentations" on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event.
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 non-small cell lung cancer (NSCLC) trial of silevertinib, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com.
From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this press release.
Contact
For Investors:
investors@bdtx.com
For Media:
media@bdtx.com
